Key ideas from Vasant Narasimhan

• Novartis spun off three public companies over six years, unlocking almost $180 billion in value by transforming from conglomerate to pure-play medicines company
• Cell therapy achieved breakthrough in autoimmune diseases with 'Lazarus-like' results - one Sentinel patient went from bedridden to no sign of disease in six months
• siRNA technology has become a 'de-risked modality' enabling once-yearly injections for cardiovascular disease, potentially revolutionizing public health access
• Zolgensma gene therapy costs over $2 million but is reimbursed in 48 countries due to extraordinary cost-effectiveness versus $10 million lifetime care costs
• China's biotech industry now matches or exceeds U.S. licensing exits, with NMPA approving first-in-human studies in under a month versus lengthy U.S. timelines
• AI has reached a tipping point in 2026 with Novartis deploying 3,000 scientists on AI platforms, turning six-month data queries into minutes
• Clinical trial documentation remains surprisingly manual with study nurses recording on paper then inputting to electronic systems - a major automation opportunity
• CMC (Chemical Manufacturing Controls) work is consistently underinvested in biotech startups, causing deal delays and requiring extensive rework by acquirers